Fabrazyme

Fabrazyme. It is a recombinant form of the human enzyme alpha-galactosidase A, used as an enzyme replacement therapy for the treatment of Fabry disease. This lysosomal storage disorder is caused by deficient activity of this specific enzyme, leading to the systemic accumulation of globotriaosylceramide and related substrates. The therapy is designed to provide the exogenous enzyme needed to catalyze the hydrolysis of these lipids, thereby alleviating the progressive cellular damage that characterizes the disease.

Medical uses

Fabrazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease. Its primary use is to reduce the deposition of globotriaosylceramide in the capillary endothelium of the kidney, heart, and other organ systems, which can slow the progression of the disease. Clinical studies, such as those monitored by the Food and Drug Administration, have demonstrated its efficacy in clearing accumulated lipids from key cell types, including those in the renal cortex and cardiac myocytes. Treatment is typically administered via intravenous infusion every two weeks, and its use is often managed through specialized metabolic disease clinics or programs like the Genzyme Humanitarian Program for access.

Adverse effects

The most frequently reported adverse reactions are infusion-associated reactions, which can include pyrexia, chills, dyspnea, and tachycardia. These symptoms are often managed by pre-medication with antihistamines or corticosteroids and by adjusting the infusion rate. Severe reactions, including anaphylaxis and cardiac arrest, have been reported in post-marketing surveillance coordinated by agencies like the European Medicines Agency. Other common adverse effects include paresthesia, headache, and fatigue. Patients may also develop IgG antibodies against the enzyme, which can potentially reduce its efficacy, a phenomenon studied extensively in trials at institutions like the National Institutes of Health.

Mechanism of action

Fabrazyme is a recombinant protein that is catalytically active and has an identical amino acid sequence to the native human enzyme. The mechanism involves the enzyme binding to mannose-6-phosphate receptors on the cell surface, which facilitates its internalization into lysosomes. Once inside these intracellular compartments, it hydrolyzes the terminal alpha-galactosyl residues from globotriaosylceramide and its derivative, globotriaosylsphingosine. This enzymatic cleavage reduces the substrate burden within lysosomes of various cell types, particularly the vascular endothelium, which is crucial for preventing the progressive ischemia and fibrosis seen in organs such as the kidney and left ventricle.

History

The development of Fabrazyme followed the identification of the genetic basis of Fabry disease and the cloning of the GLA gene encoding alpha-galactosidase A. The recombinant enzyme was developed by the biotechnology company Genzyme, now part of Sanofi. It received its first regulatory approval from the Food and Drug Administration in 2003, following clinical trials that demonstrated clearance of globotriaosylceramide from key tissues. Its approval in the European Union followed soon after, overseen by the European Medicines Agency. The therapy's history is also marked by significant manufacturing challenges, including a major supply shortage in 2009 that led to rationing and heightened regulatory scrutiny by the FDA.

Society and culture

The high cost of Fabrazyme has made it a focal point in debates about drug pricing and access to orphan drugs for rare diseases. Its development was supported by the Orphan Drug Act, which provides incentives for treatments targeting conditions like Fabry disease. The therapy has been featured in discussions on healthcare policy in systems such as the National Health Service and by payers like Medicare. Patient advocacy groups, including the National Fabry Disease Foundation, have played a significant role in raising awareness and supporting affected individuals. The drug's brand name is recognized in popular culture through its inclusion in discussions about biomedical innovation on programs like 60 Minutes.

Category:Enzymes Category:Orphan drugs Category:Sanofi